Lipid Accumulation Product Index As a Marker of Metabolic Syndrome in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis Publisher Pubmed



Seyedi SA ; Nabipoorashrafi SA ; Amin Afshari S ; Mansouri A ; Alizadegan D ; Hobaby S ; Esmaeilpur Abianeh F ; Mechanick JI ; Esteghamati A
Source: Endocrinology, Diabetes and Metabolism Published:2025

Abstract

Background: Lipid accumulation product (LAP) index is a measure of lipid toxicity based on triglyceride and waist circumference. The aim of the current study is to explore the relationship between LAP index and metabolic syndrome (MetS) among women with polycystic ovary syndrome (PCOS) in a systematic review and meta-analysis. Methods: Web of Science, Embase and PubMed online databases were systematically searched for studies investigating the relationship between LAP index and MetS in PCOS. Ten observational studies, including 12 populations with 2957 individuals, were identified for analysis. Mean difference and bivariate diagnostic test accuracy (DTA) meta-analyses were performed. Results: A significant LAP index difference of 49.17 was found in women with PCOS with and without MetS (95% CI [40.57, 57.77]). By DTA meta-analysis, the pooled sensitivity and specificity of LAP index for MetS detection were 87% (I2 78%, 95% CI [80%, 92%]) and 88% (I2 78%, 95% CI [83%, 92%]), respectively, with area under the curve of 0.94 (95% CI [0.91, 0.96]). Conclusion: The LAP index is an affordable, specific and sensitive marker for MetS and may be considered a pragmatic tool for MetS detection among patients with PCOS, particularly those with an insulin resistance endotype. © 2025 Elsevier B.V., All rights reserved.